H

P

HERRERA , Pilar

Last name: HERRERA

First name: Pilar

November 24, 2022 (v1)

Publication

Metadata-only

Phase II Trial of Allogeneic Transplantation Plus Novel Drugs in Multiple Myeloma: Effect of Intensifying Reduced-Intensity Conditioning with Bortezomib and Adding Maintenance Treatment

Reinoso-Segura, Marta Caballero Velázquez, Teresa Herrera, Pilar

The use of reduced-intensity conditioning (RIC) regimens has decreased the risk of nonrelapse mortality (NRM) after allogeneic stem cell transplantation (alloSCT). In contrast, disease relapse remains the most frequent cause of treatment failure and death. Owing to both their antimyeloma effect and immunomodulatory properties, novel drugs could...

Uploaded on: December 4, 2022
November 24, 2022 (v1)

Publication

Metadata-only

Phase II Trial of Allogeneic Transplantation Plus Novel Drugs in Multiple Myeloma: Effect of Intensifying Reduced-Intensity Conditioning with Bortezomib and Adding Maintenance Treatment

Reinoso-Segura, Marta Caballero Velázquez, Teresa Herrera, Pilar

The use of reduced-intensity conditioning (RIC) regimens has decreased the risk of nonrelapse mortality (NRM) after allogeneic stem cell transplantation (alloSCT). In contrast, disease relapse remains the most frequent cause of treatment failure and death. Owing to both their antimyeloma effect and immunomodulatory properties, novel drugs could...

Uploaded on: December 4, 2022